TY - JOUR
T1 - Dietary intake of isoflavones and breast cancer risk by estrogen and progesterone receptor status
AU - Zhang, Min
AU - Yang, H.
AU - Holman, D'Arcy
PY - 2009
Y1 - 2009
N2 - Epidemiological and experimental studies suggest that isoflavones may protect against breast cancer by acting as estrogen agonists or antagonists. A case-control study was conducted in southeast China in 2004–2005 to examine the association between dietary isoflavone intake and breast cancer risk by estrogen receptor (ER) and progesterone receptor (PR) status. The incident cases were 756 female patients with histologically confirmed breast cancer. The 1,009 age-matched controls were healthy women randomly recruited from outpatient breast clinics. We assessed isoflavone intake by face-to-face interview using a validated and reliable food-frequency questionnaire and obtained tumor ER and PR status from pathologic reports. Compared with women in the lowest intake quartiles, those in the highest quartile of total isoflavone intake had a reduced risk of all receptor status subtypes of breast cancer with a dose-response relationship. The adjusted ORs (95% CIs) were 0.39 (0.27–0.58) for ER+, 0.32 (0.21–0.49) for ER−, 0.43 (0.29–0.64) for PR+, and 0.30 (0.19–0.45) for PR− (P for trend
AB - Epidemiological and experimental studies suggest that isoflavones may protect against breast cancer by acting as estrogen agonists or antagonists. A case-control study was conducted in southeast China in 2004–2005 to examine the association between dietary isoflavone intake and breast cancer risk by estrogen receptor (ER) and progesterone receptor (PR) status. The incident cases were 756 female patients with histologically confirmed breast cancer. The 1,009 age-matched controls were healthy women randomly recruited from outpatient breast clinics. We assessed isoflavone intake by face-to-face interview using a validated and reliable food-frequency questionnaire and obtained tumor ER and PR status from pathologic reports. Compared with women in the lowest intake quartiles, those in the highest quartile of total isoflavone intake had a reduced risk of all receptor status subtypes of breast cancer with a dose-response relationship. The adjusted ORs (95% CIs) were 0.39 (0.27–0.58) for ER+, 0.32 (0.21–0.49) for ER−, 0.43 (0.29–0.64) for PR+, and 0.30 (0.19–0.45) for PR− (P for trend
U2 - 10.1007/s10549-009-0354-9
DO - 10.1007/s10549-009-0354-9
M3 - Article
C2 - 19252980
SN - 0167-6806
VL - 118
SP - 553
EP - 563
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 3
ER -